Global Remicade Biosimilars Market
A biosimilar refers to a biotherapeutic product that is similar to an existing licensed reference therapeutic drug, in terms of quality, efficacy, and safety. Biological products are the fastest-growing class of therapeutic products, as they offer additional treatment options and aid in lowering healthcare costs. Biosimilars are almost identical copies of the originally approved drugs and can be manufactured only when the patent for the original innovator drug expires. These products are highly sensitive to smallest changes in manufacturing procedure, as these drugs possess high molecular complexity. However, Remicade (Infliximab) refers to a chimeric monoclonal antibody biologic licensed by the U.S. FDA in 1998, as an innovative product indicated for the treatment of Crohn’s disease in adults and children. The monoclonal antibody drug was first developed in partnership by Janssen Biotech, Inc. and Merck & Co. The Remicade was later approved for its use in the treatment of ulcerative colitis, plague psoriasis, rheumatic arthritis, and spinal psoriatic arthritis in combination with methotrexate. Later, various pharmaceutical manufacturers developed biosimilars to infliximab, which lowered market share of Remicade due to cost-effective prices.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1769
Global Remicade Biosimilars Market Dynamics
Increasing incidence of autoimmune diseases, such as plaque psoriasis and rheumatoid arthritis, are projected to drive the growth of the global Remicade biosimilars market. According to the American Autoimmune Related Disease Association, around 50 million Americans suffered from autoimmune diseases in the U.S. in 2017. Moreover, faster reaction rates of these biosimilars due to their availability in the form of intravenous mode of administration is further expected to increase the adoption of Remicade biosimilar over the forecast period. Furthermore, patent expiry of the branded versions is expected to increase the number of biosimilars for its branded counterparts thereby increasing the demand for Remicade biosimilar. However, stringent regulatory guidelines for development of these biosimilars as well as side effects of these drugs leading to risk of hospitalization are expected to restrain the global Remicade biosimilars market development.
Global Remicade Biosimilars Market – Regional Insights
Europe holds a dominant position in the global Remicade biosimilars market and is expected to retain its dominance throughout the forecast period, owing to the presence of top market players in the region, rapid penetration of biosimilars into the European market, as well as a high adoption rate of biosimilars due to lower prices. For instance, in 2018, Sandoz, a Novartis division, received European Commission (EC) approval for Zessly (infliximab) a Remicade biosimilar for use in Europe. The successive research and speedy approvals by the U.S. regulatory authorities for market entry of biosimilars in North America is expected to drive growth of the market over the forecast period. Furthermore, in December 2017, Pfizer, Inc. received the U.S. FDA approval for its second biosimilar, Ifixi, to treat rheumatoid arthritis.
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1769
Asia Pacific is expected to witness significant growth in the global Remicade biosimilars market over the forecast period, owing to developments in healthcare infrastructure and the U.S. FDA approval of Remicade (infliximab) biosimilars by regional players to market the products internationally. For instance, in April 2016, Celltrion, a South Korea-based manufacturing company, received the U.S. FDA approval for intravenously administered version of the rheumatoid arthritis drug, sold under the name ‘Infllectra’. Moreover, major investments by regional players for research and development of biosimilar production is expected to drive market growth in the region. In October 2016, Cipla, Inc. invested US$ 8 million to set up a manufacturing plant for biosimilars in South Africa.
Global Remicade Biosimilars Market – Competitive Scenario
The key players operating in the global Remicade biosimilars market include Janssen Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp Pharmaceuticals, and others. These market players are focused on introducing maximum number of biosimilar for multiple indications to retain their position in the global market. For instance, in July 2017, Merck & Company, Inc., in collaboration with Samsung Bioepis, introduced Renflexis (infliximab-abda), a biosimilar to Remicade for the treatment of moderate to severe Crohn’s disease, active ulcerative colitis, rheumatoid arthritis, and other few disease indications.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/remicade-biosimilars-market-1769
On the basis of disease indication:
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Crohn’s Disease
- Psoriatic Arthritis
- Plaque Psoriasis
Based on geography:
- North America
- Latin America
- Asia Pacific
- Middle East
Have a Look at Related Research Insights:
ANTIDIABETIC BIOSIMILARS MARKET ANALYSIS
BIOSIMILARS MARKET ANALYSIS
BIOPROCESS ANALYZER MARKET ANALYSIS
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at [email protected]